Fed Pullback Pledge...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$2.36 -0.07 | -2.88%
06/19/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 36.41M | 47.31M | 29.22M | 25.20M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 36.41M | 47.31M | 29.22M | 25.20M |
| Selling, General, and Administrative Expenses | 13.85M | 13.37M | 13.48M | 13.32M |
| Research & Development | 33.97M | 45.01M | 47.03M | 49.50M |
| Operating Income before D & A (EBITDA) | -11.40M | -11.07M | -31.29M | -37.61M |
| Depreciation & Amortization | 2.38M | 1.74M | 2.56M | 2.61M |
| Interest Income | 445.00K | 317.00K | 619.00K | 1.09M |
| Other Income - Net | 113.00K | 20.00K | 266.00K | 1.59M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -13.23M | -12.47M | -32.96M | -37.54M |
| Interest Expense | 26.00K | 25.00K | 274.00K | 655.00K |
| Pre-Tax Income | -13.26M | -12.50M | -33.23M | -38.20M |
| Income Taxes | 0.00 | 0.00 | -550.00K | 550.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -10.87M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -10.87M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -10.87M | -10.76M | -30.13M | -36.14M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-10.87M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -10.87M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.18 | -0.20 | -0.68 | -0.82 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.18 | -0.20 | -0.68 | -0.82 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.18 | -0.20 | -0.68 | -0.82 |
| Basic Normalized Net Income/Share | -0.18 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.18 | -0.20 | -0.68 | -0.82 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.18 | -0.20 | -0.68 | -0.82 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.18 | -0.20 | -0.68 | -0.82 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.18 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARQL
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserD-ZYRE
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
Latest ARQL Headlines from TheStreet
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- 5 Under-$10 Stocks Setting Up to Trade Higher 11.30.12 | 12:11 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Stocks Drop on Eurozone, Earnings Anxieties 10.02.12 | 02:10 pm
- Arqule Shutters Lung Cancer Study Early Due to Futility 10.02.12 | 07:10 am
- Arqule Shares Slide on Lung Cancer Drug Safety Concern 08.29.12 | 10:08 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
Press Releases for ARQL
- ArQule Reports Fiscal 2012 Year End And Fourth Quarter Results - Business Wire 03.14.13 | 07:03 am
- ArQule To Report Fiscal 2012 Financial Results On March 14, 2013 - Business Wire 03.07.13 | 08:03 am
- ArQule, Inc. To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.27.13 | 08:02 am
- ArQule, Inc. To Present At RBC Capital Markets Global Healthcare Conference - Business Wire 02.19.13 | 08:02 am
- ArQule, Inc. To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 08:02 am
- Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib - Business Wire 01.31.13 | 08:01 am
- Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer - Business Wire 01.11.13 | 07:01 am
- ArQule Enrolls First Patient In Phase 1 Trial With ARQ 087, An FGFR Inhibitor - Business Wire 12.13.12 | 08:12 am
- ArQule, Inc. To Present At Oppenheimer Healthcare Conference - Business Wire 12.05.12 | 04:12 pm
- ArQule, Inc. To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
Partner Headlines for ARQL
- ArQule Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.08.13 | 10:05 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.03.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 08.07.12 | 09:08 am
- Teradyne DROPS 16% in Recent Weeks and 4 Fresh Analyst Insights - Wall St. Cheat Sheet 07.06.12 | 01:07 pm
- Five Stocks With Heavy Insider Trading - Benzinga 06.11.12 | 01:06 pm
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
